Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Any faculty member wishing to commercialize a discovery or technology should contemplate the pros and cons of pursuing the entrepreneurial route or licensing to an outside entity.
A serial entrepreneur learns that the world's most exciting, groundbreaking technology is pointless if it is unable to address an urgent and relevant need.
Academic researchers often need to stand out to advance, but the corporate world calls for team players. Moving from one world to the other can be a culture shock.
Locking in a potential partner and executing a license for development and commercialization requires honed negotiation skills. Here's how not to blink.
Securing a partner is only the beginning—you then have to put substantial effort and resources into keeping the collaboration functioning and productive.
Faced with limited funding and the need to find the most time- and cost-efficient route to proof of concept and relevance, how should you reorganize your company to facilitate development of your most valuable assets?
Numerous challenges face any emerging company developing a biopharmaceutical. How you anticipate hurdles, plan for contingencies and communicate with stakeholders will play a big part in determining your success.
Business plan competitions can earn you more than a plaque for the wall and a pat on the back—they can provide start-up money, experience and the attention your idea needs to get off the ground.
There is a common misperception that only medium- and large-cap biotechs need to understand and interact with the media. As investor demands increase and partnering dynamics evolve, startups need to understand the art of media relations more now than ever before.
